Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 29, 2013

Primary Completion Date

May 24, 2017

Study Completion Date

April 29, 2019

Conditions
Leukemia, Hairy Cell
Interventions
DRUG

Moxetumomab pasudotox

DRUG

IV Bag Protectant for Moxetumomab pasudotox

Trial Locations (34)

2060

Research Site, Antwerp

5099

Research Site, Bergen

9000

Research Site, Ghent

10065

Research Site, New York

11000

Research Site, Belgrade

13353

Research Site, Berlin

14033

Research Site, Caen

16132

Research Site, Genova

20122

Research Site, Milan

20892

Research Site, Bethesda

21287

Research Site, Baltimore

31048

Research Site, Haifa

33136

Research Site, Miami

33604

Research Site, Pessac

35392

Research Site, Giessen

40138

Research Site, Bologna

53100

Research Site, Siena

60611

Research Site, Chicago

67098

Research Site, Strasbourg

69120

Research Site, Heidelberg

69310

Research Site, Pierre-Bénite

76038

Research Site, Rouen

77030

Research Site, Houston

78157

Research Site, Le Chesnay

87131

Research Site, Albuquerque

90095

Research Site, Los Angeles

91010

Research Site, Duarte

T6G 2G7

Research Site, Edmonton

625 00

Research Site, Brno

DUBLIN 8

Research Site, Dublin

80-952

Research Site, Gdansk

93-510

Research Site, Lodz

08036

Research Site, Barcelona

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT01829711 - Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | Biotech Hunter | Biotech Hunter